Pub. Date : 2015
PMID : 25990337
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Patients with ALK rearrangements treated with specific ALK inhibitors such as crizotinib or EGFR-activating mutations treated with gefitinib, erlotinib or afatinib have improved progression-free survival and better quality of life than patients treated with chemotherapy. | Erlotinib Hydrochloride | ALK receptor tyrosine kinase | Homo sapiens |
| 2 | Patients with ALK rearrangements treated with specific ALK inhibitors such as crizotinib or EGFR-activating mutations treated with gefitinib, erlotinib or afatinib have improved progression-free survival and better quality of life than patients treated with chemotherapy. | Erlotinib Hydrochloride | ALK receptor tyrosine kinase | Homo sapiens |